iNCOVACC: All you need to know about world's first intranasal Covid vaccine

The vaccine been approved for use as a primary as well as a heterologous (mix-and-match) booster dose in India

Bharat Biotech's iNCOVACC, Bharat Bio's nasal Covid vaccine, nasal Covid vaccine, Covid vaccine
iNCOVACC (BBV154) is India's first intranasal Covid-19 vaccine, and can be used for easy and painless immunisation against coronavirus.
BS Web Team New Delhi
2 min read Last Updated : Jan 27 2023 | 5:26 PM IST
India launched its first intranasal Covid-19 vaccine named iNCOVACC, on Thursday, January 26. Manufactured by Hyderabad-based Bharat Biotech, the intranasal vaccine was launched by Union Health Minister Mansukh Mandaviya and Union Minister of Science & Technology Jitendra Singh on India's 74th Republic Day.

The vaccine has been approved for use as a primary as well as a heterologous (mix-and-match) booster dose in India.

Here's everything you need to know about India's first intranasal vaccine for coronavirus:

What is iNCOVACC?

iNCOVACC (BBV154) is India's first intranasal Covid-19 vaccine, and can be used for easy and painless immunisation against coronavirus. According to its manufacturer, Bharat Biotech, iNCOVACC blocks both infection and transmission of coronavirus by stimulating a broad immune response.

The Drug Controller General of India (DCGI) approved the vaccine for limited emergency use as a heterologous booster dose in adults in November last year.

The launch of iNCOVACC comes alongside increased concerns of a new coronavirus variant, BF.7. that has led to a surge of Covid cases in China and may spread in India.

"The launch of Incovacc is an important milestone under Aatmanirbhar Bharat efforts; today, India contributes 65 per cent of the vaccines for the world," Mandaviya said at the vaccine's launch on Thursday.

What is the price of iNCOVACC ?

The intranasal Covid vaccine was initially to be administered at private hospitals only. However, Bharat Biotech later announced that iNCOVACC has been priced at Rs 325 for national and state governments, while for private hospitals and institutions, it is available at Rs 800 per dose. The intranasal vaccine is now also available on CoWIN, says its manufacturer Bharat Biotech.

It should be noted that iNCOVACC does not require syringes, alcohol wipes, bandage, etc, thus saving the costs related to procurement, distribution, storage, and biomedical waste disposal.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineBharat Biotechgovernment of India

Next Story